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Abstract
Introduction: Idiopathic purpura fulminans is a cutaneous thrombotic disorder usually caused by autoimmune-
mediated protein C or S deficiency. This disorder typically presents with purpura and petechiae that eventually
slowly or rapidly coalesce into extensive, necrotic eschars on the extremities. We present the first known case of
idiopathic purpura fulminans consistent with prior clinical presentations in the setting of a prothrombotic genetic
mutation, but without hallmark biochemical evidence of protein C or protein S deficiency. Another novel feature of
our patient’s presentation is that discontinuation of anti-coagulation has invariably led to recurrence and formation
of new lesions, which is unexpected in idiopathic purpura fulminans because clearance of autoimmune factors
should be followed by restoration of anti-coagulant function. Although this disease is rare, infants with suspected
idiopathic purpura fulminans should be rapidly diagnosed and immediately anti-coagulated to prevent adverse
catastrophic outcomes such as amputation and significant developmental delay.
Case presentation: A six-month-old Caucasian boy was brought to our pediatric hospital service with a low-grade
fever and subacute, symmetric, serpiginous, stellate, necrotic eschars on his forearms, legs and feet that eventually
spread non-contiguously to his toes, thighs and buttocks. In contrast to his impressive clinical presentation, his
serologic evaluation was normal, and he was not responsive to corticosteroids and antibiotics. Full-thickness skin
biopsies revealed dermal vessel thrombosis, leading to a diagnosis of idiopathic purpura fulminans and successful
treatment with low-molecular-weight heparin, which was transitioned to warfarin. Long-term management has
included chronic anti-coagulation because of recurrence of lesions with discontinuation of treatment.
Conclusion: In infants with necrotic eschars, it is important to first consider infectious, inflammatory and
hematologic etiologies. In the absence of etiology for protracted idiopathic purpura fulminans, management
should include tissue biopsy, in which thrombotic findings warrant a trial of empiric anti-coagulation. Some infants,
including our patient, may need long-term anti-coagulation, especially when the underlying etiology of
coagulation remains unidentified and symptoms recur when treatment is halted. Given that our patient still
requires anti-coagulation, he may have a yet to be identified autoimmune-mediated mechanism for his truly
idiopathic case of protracted purpura fulminans.
Introduction
Purpura fulminans (PF) is caused by a relative deficiency
in protein C-mediated hemostasis and is classified by etiol-
ogy and history into neonatal PF, acute infectious PF and
idiopathic or post-infectious PF. Neonatal PF is caused
by homozygous or compound heterozygous deficiencies
in protein C or protein S and manifests shortly after
birth [1]. In contrast, acute infectious PF occurs at any age
and is most likely a consequence of coagulative consump-
tion of protein C, protein S and anti-thrombin III during
sepsis [2,3]. It is considered a dermatologic manifestation
of endotoxin-triggered hemostatic abnormalities (specifi-
cally, induced protein C and S deficiency) associated with
sepsis and disseminated intravascular coagulation (DIC),
most frequently in the setting of serogroup C meningococ-
cemia and endotoxemia [4,5]. * Correspondence: macheret.fima@mayo.edu
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to the development of anti-protein S antibodies, which
form antibody-protein S complexes that are excreted,
leading to transient protein S deficiency, hypoactivation
of the protein C pathway and dermal vessel hypercoa-
gulability. Important evidence suggests a post-infectious
etiology. After D’Angelo et al. [6] identified autoantibo-
dies to protein S in a boy with thromboembolic disease
antecedent to varicella infection, Levin et al. [7] discov-
ered and quantified protein S autoantibodies in four
children with idiopathic PF following varicella infection.
Indeed, Regnault et al. [8] confirmed that protein S
autoantibodies obtained from a child with idiopathic PF
antecedent to varicella infection caused a hypercoagul-
able state in vitro. All of the patients in the Levin et al.
[7] case series had minimal or undetectable protein S
and protein S activity. Some of the patients in the Levin
et al. series had other laboratory abnormalities, includ-
ing elevated anti-cardiolipin immunoglobulin M (IgM)
and IgG antibodies, IgG-containing immune complexes,
decreased C4B binding protein and decreased protein C
activity.
Despite the important work by D’Angelo et al. [6] and
Levin et al. [7] with regard to post-varicella etiology,
there may be other anti-coagulant factors involved in the
disease process. The independent contribution of hetero-
zygous prothrombin G20210 mutations to the develop-
ment of autoimmune protein S deficiency and idiopathic
PF is still unclear. This mutation has been reported in
two cases of idiopathic PF and autoantibodies to protein
S with decreased protein S levels [9,10]. The presence of
anti-phospholipid antibodies has also been reported in
conjunction with protein S deficiency and thrombosis in
children [11]. These cases underscore that work-up for
suspected idiopathic PF should include clotting factor
assessment, rheumatologic evaluation and thrombophilic
mutation analysis.
Case presentation
A previously healthy six-month-old Caucasian boy was
brought to our pediatric hospital service for a second opi-
nion regarding a six-week history of necrotic skin lesions
on his upper and lower extremities. The lesions were
initially petechial and rapidly evolved into escharotic pla-
ques over a 10-day period. They were accompanied by
the onset of a low-grade intermittent fever and night
sweats. One month after his initial presentation, the
lesions had spread to involve the distal, dorsal surface of
his feet and toes. His parents denied any trauma, burns
or other inciting injuries.
H eh a da ne x t e n d e df a m i l yh i story of stroke, miscar-
riages, deep venous thromboses, pulmonary emboli and
multiple sclerosis, but his parents denied any coagulopa-
thies, bleeding disorders or rheumatologic diseases. His
social history was non-contributory. His vaccinations were
up-to-date, and he had received his most recent ones
about three weeks before the onset of the lesions, which
included vaccinations for diphtheria-tetanus-acellular
pertussis, haemophilus influenzae type B, inactivated polio
vaccine, hepatitis B virus, heptavalent pneumococcal vac-
cine and rotavirus vaccine.
Outside investigations included a negative skeletal sur-
vey and normal laboratory studies. He received a short,
unsuccessful course of methylprednisolone. At the time of
presentation, his only other medications were ranitidine
(One and a half mg/kg/day) and omeprazole (0.67 mg/kg/
day) for gastroesophageal reflux disease and lactulose for a
recent history of constipation that began after rice cereal
was added to his diet.
Upon admission to our hospital, his physical examina-
tion revealed an infant who was alert, active and intermit-
tently fussy. His vital signs were heart rate 128 beats/
minute, blood pressure 126/94 mmHg, respiratory rate 42
breaths/minute and body temperature 36.9°C. His skin
examination revealed blackened, eschar-like, linear but
serpiginous, stellate, spatially non-contiguous lesions with
peripheral yellow crusting. There were symmetrical necro-
tic plaques on his forearms, distal legs, dorsal surface of
his feet and his toes, including the first two toes on each
foot (Figures 1a and 1b). Otherwise his physical examina-
tion was non-contributory.
The results of our initial laboratory investigation are
shown in Table 1. Additionally, a peripheral smear
revealed Döhle bodies with toxic granulations. Serum pro-
tein electrophoresis revealed hypogammaglobulinemia
(g-globulins 0.3 g/dL). Serial blood cultures were negative
for bacteria and fungi.
Punch biopsies from all four limbs revealed a pauci-
inflammatory occlusive vasculopathy. Direct immuno-
fluorescence showed strong IgM staining in the superfi-
cial and mid-dermal vessels, weak C3 staining in a few
superficial vessels and some fibrinogen deposition in the
superficial and mid-dermal vessels. Staining for IgG and
IgA was negative. Excisional biopsy tissue was cultured
and revealed anaerobic Gram-positive cocci (3+), enter-
ococci (3+), Neisseria animaloris (2+) and a few white
blood cells, and stains of the biopsy were negative for
acid-fast organisms, mycobacterium, and fungi. Immu-
nofluorescence staining was negative for IgG, C3 and
fibrinogen, while IgA stained weakly positive in rare der-
mal blood vessels and IgM stained positive in a few
scattered blood vessels in the dermis.
The patient was dischargedo nw e t - t o - d r yd r e s s i n g
changes, and his laboratory abnormalities at dismissal
are shown in Table 1. Prednisolone therapy was tapered
over two weeks.
The patient was re-admitted one week later because of
progression of his skin disease. Flexion contractures
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at readmission are shown in Table 1. Genetic analysis
revealed that he was a heterozygous carrier of the pro-
thrombin 20210A mutation. Further imaging included
computed tomography of the chest and abdomen, which
were unrevealing. Additional viral and retroviral studies
were all negative, including varicella. His oxidative burst
test was also normal. CD11a was not indicative of leu-
kocyte adhesion deficiency. Tests for arsenic, lead, mer-
cury and cadmium were all negative.
Discussion
After the extensive negative work-up and given the lack
of a definitive diagnosis, a peripheral inserted central
catheter line was placed for the initiation of high-dose
IV prednisone (Four mg/kg/day). He was started empiri-
cally on IV ampicillin/sulbactam (200 mg/kg/day, seven-
day course). Corticosteroids were tapered over the next
seven days.
One week later he showed no clinical improvement.
Following interdisciplinary conference and consultation
with pediatric coagulation experts, we decided to treat
him empirically for idiopathic purpura fulminans with
dalteparin (two SQ doses at 250 U/kg/day). This
regimen was adjusted to 350 U/kg/day divided into two
SQ doses to achieve a therapeutic heparin level. Acetyl-
salicylic acid was also added. Physical therapists were
consulted because of motor skill regression with skin
contractures.
At his follow-up examination one week later, his par-
ents reported that no new lesions had developed. The
eschars had begun to regress centrifugally from their
borders, revealing healing pink scars, especially in his
upper extremities. After several weeks, peripheral areas
of crusting had shed, revealing healed, scarred skin
(Figures 2a and 2b).
Follow-up at two months demonstrated dramatic heal-
ing (Figures 3a and 3b). While on heparin therapy, he
had transient recurrence of petechiae one day after
receiving an H1N1 virus vaccination. Any attempt to
reduce the low-molecular-weight heparin from twice to
once daily led to symmetric recurrence of lesions on his
buttocks and thighs. He was transitioned to chronic
anti-coagulation with warfarin 1 mg/day, and the lesions
have been well controlled when his international nor-
malized ration is in the therapeutic range of two to
three. Subsequent urine amino acid analysis and geno-
mic microarray analyses were unremarkable.
About one year after initial presentation, our patient
was experiencing developmental delays that were espe-
cially noted in gross motor function. Neurology consul-
tation was sought, and their work-up revealed proximal
muscle weakness and areflexia. Further investigation
revealed that he is heterozygous for a duplication of a
thymine nucleoside in his SMN1 gene at position 91 in
codon 31, which causes a frame shift mutation and is
consistent with spinal muscular atrophy.
The differential diagnosis for an infant with necrotic
skin lesions is listed in Table 2. After interdisciplinary
consultation, we arrived at a diagnosis of idiopathic PF,
a rare prothrombotic syndrome characterized by throm-
bosis of dermal vasculature and progressive, widespread
purpura with necrosis. Our patient’s extensive character-
istic lesions and stereotypical features on skin biopsy
were consistent with those described in prior reported
cases. Indeed, our patient’s impressive response to anti-
coagulation was strikingly similar to that described in
prior cases and argues in favor of this diagnosis.
The most novel divergence of our patient’si d i o p a t h i c
PF from prior cases was the disparity in laboratory evi-
dence. Fascinatingly, our patient had no absolute or
relative deficiencies in protein C and S levels or activ-
ities, features present in the prior reported cases. Protein
C activity was measured using venom activator and
chromogenic peptide substrate; therefore, it is possible
that a congenital protein C variant may not have been
identified that would require a clot-based assay. Protein
S antigen was measured using free protein S assay, and
Figure 1 Necrotic skin lesions at time of first admission.R i g h t
forearm is shown in the top panel, and right leg and foot are
displayed in the bottom panel.
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a
Test or laboratory evaluation Admission 1 (dismissal 1)
b Admission 2 Reference range
Hemoglobin 13.1 (9.6
c)g/dL 11.5 g/dL 10.5 to 13.5 g/dL
Hematocrit 37.5 (27.6
c)% 34.0% 33.0% to 44.0%
Leukocytes 16.5
c (15.7
c)×1 0
9/L 26.3 × 10
9/L
c 6t o1 1×1 0
9/L
Thrombocytes 738
c (651
c)×1 0
9/L 951 × 10
9/L
c 150 to 450 × 10
9/L
Neutrophils 11.41
c (6.47) × 10
9/L - 1.5 to 8.5 × 10
9/L
Lymphocytes 3.91
c (7.65) × 10
9/L - 4.0 to 10.5 × 10
9/L
Monocytes 1.09 (1.42
c)×1 0
9/L - 0.05 to 1.1 × 10
9/L
Eosinophils 0.00
c (0.05) × 10
9/L - 0.05 to 0.7 × 10
9/L
PT 9.8 seconds 9.6 seconds 8.3 to 10.8 seconds
aPTT 30 seconds 30 seconds 21 to 33 seconds
Thrombin time 20 seconds 22 seconds 16 to 25 seconds
Protein C, activity 99% 120% 70% to 150%, adults
Protein S, free 116 144 65% to 160%, men
Protein S, activity 123% 123% 65% to 160%, adults
Anti-thrombin activity 119% 136%
c 80% to 130%, > 6 months old
D-dimer 200 ng/mL < 250 ng/mL
Fibrinogen 315 mg/dL 351 mg/dL 200 to 375 mg/dL
DRVVT 1.0 < 1.2
APC ratio 3.1 > 2.3
Factor VIII 170% 55% to 205%, adults
Ristocetin co-factor 92% 55% to 200%, adults
von Willebrand factor 112% -
ESR 11 mm/hour 25 mm/hour -
CRP 5.6 mg/L 9.1 mg/L
c < 8.0 mg/L
ANA antibody 0.1 U < 1.0
Homocysteine 7 μmol/L 5 μmol/L < 13 μmol/L
Anti-phospholipid/anti-cardiolipin, IgM < 4.0 -
-IgG < 4.0 -
AST 27 U/L
c 24 U/L 8 to 20 U/L
ALT 18 U/L 15 U/L 8 to 20 U/L
ACE 16 U/L 8 to 53 U/L
Cryofibrinogen Neg Neg
Cryoglobulin Neg Neg
Plasma porphyrins < 1 U/L < 1 U/L
RBC ALA dehydratase 8.7 nmol/L/second -
Myeloperoxidase < 0.2 U < 0.2 U < 0.4 U
Proteinase 3 < 0.2 U < 0.2 U < 0.4 U
Total protein 5.3 g/dL
c 6.0 to 7.8 mg/dL
Albumin 3.0 g/dL
c 3.5 to 5.5 mg/dL
Sodium ion 138 mmol/L 135 to 145 mmol/L
Potassium ion 5.2 mmol/L
c 3.5 to 5.0 mmol/L
Bicarbonate ion 19 mmol/L 18 to 23 mmol/L
Chloride 105 mmol/L 95 to 105 mmol/L
BUN 9 mg/dL
c 3 to 7 mmol/L
Creatinine 0.2 mg/dL
c 0.7 to 1.0 mg/dL
GGT 19 U/L 5 to 40 U/L
Anion gap 14 mEq/L
c 8 to 12 mEq/L
Glucose 107 mg/dL
c 70 to 99 mg/dL
Bilirubin (total/direct) 0.2/0.1 mg/dL 0.1 to 1.0/0.0 to 0.3 mg/dL
IgM 80 mg/dL 67 mg/dL 24 to 267 mg/dL
IgG 272 mg/dL 289 mg/dL 164 to 588 mg/dL
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a (Continued)
IgA 130 mg/dL
c 16 to 50 mg/dL
IgE 7.5 kU/L < 30 kU/L
Complement C3 128 mg/dL 75 to 175 mg/dL
-C4 134 mg/dL
c 14 to 40 mg/dL
Fc C7 59 U/mL 36 to 60 U/mL
-C8 60 U/mL
c 33 to 58 U/mL
-C9 61 U/mL 37 to 61 U/mL
b2 microglobulin 5.6 μg/mL 0.70 to 1.80 μg/mL
Zinc 0.67 μg/mL 0.6 to 1.20 μg/mL
a1-anti-trypsin 144 mg/dL 89 to 230 mg/dL
Cold agglutinin (Negative)
Mycoplasma IgM 0.10 < 0.90
-IgG 0.5 -
aPT, prothrombin time; aPTT, activated partial thromboplastin time; DRVVT, dilute Russell’s viper venom test; APC, activated protein C; ESR, erythrocyte
sedimentation rate; CRP, C-reactive protein; ANA, anti-nuclear; IgM, immunoglobulin M; AST, aspartate aminotransferase; ALT, alanine aminotransferase; ACE,
angiotensin-converting enzyme; RBC ALA, red blood cell Δ-aminolevulinic acid; BUN, blood urea nitrogen; GGT, g-glutamyl transferase; Fc, functional component;
bvalues in parentheses are those which occurred at first discharge, which was approximately one week after first admission. The second admission occurred 1
week after the first discharge.
coutside normal limits.
Figure 2 Healing skin lesions one week after initiation of anti-
coagulation. Both arms are shown in the top panel. Right leg and
right foot are displayed in the bottom panel. No new lesions had
formed, and pink, healing scars had begun to form under the
eschars.
Figure 3 Healing skin lesions two months after initiation of
therapy. Both arms are shown in the top panel. Left leg and left
foot are shown in the bottom panel. Eschars have completely given
way to pink, healing scars with no new lesions formed.
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point. This protein S assay can be affected by the pre-
sence of lupus anti-coagulant or a specific factor V inhi-
bitor, but we did not identify either of these humoral
factors.
Also, the peripheral smear abnormalities, especially
the Döhle bodies, can be associated with DIC-linked
purpura fulminans, yet we saw no evidence of consump-
tive coagulopathy characteristic of DIC. The specific
role of N. animaloris in the progression of his lesions
remains undefined. He may have a novel form of idio-
pathic PF, possibly preceded by an unidentified infection
o rc a u s e db yad e f e c ti np r o t e i nSt h a tw ew e r eu n a b l e
to detect using conventional laboratory assays. We are
also unable to assess the potential contribution of his
series of vaccines to his disease presentation, and
although it would be unlikely for a child to develop
autoantibodies before 6 months of age, we do not rule
out the possibility that he may have developed autoanti-
bodies after immunization.
Another important aberration in the patient’s presenta-
tion was his age, because he was older than the expected
age for neonatal PF and younger than all of the other
reported cases of idiopathic PF that we reviewed. While
our patient’s initial response to anti-coagulation therapy
was the aspect of his presentation and outcome, which fit
most closely with that of idiopathic PF, his long-term
need for anti-coagulation is not consistent with the pre-
viously described etiology of this disease.
The photographs associated with this case offer a dra-
matic example of clinical management for the pediatri-
cian or dermatologist who may see similar lesions in a
non-septic infant with an unrevealing laboratory evalua-
tion. The decision to empirically anti-coagulate repre-
sented our best scientific response to the overlapping
and non-specific findings for idiopathic PF.
In light of his impressive response to treatment as
depicted in the final set of images (Figure 3), we wish to
highlight an evidence-based approach to empiric treat-
ment of idiopathic PF. Table 3 summarizes the patient
age, gender, protein S levels, varicella status, treatments
and outcomes of several recent cases reported after the
Francis case series [12]. On the basis of the hypothesized
etiology of the disease, that is, the development of protein
S autoantibodies with thrombogenesis, treatment should
include plasmapheresis with intravenous immunoglobu-
lin to eliminate protein S autoantibodies and heparin to
improve hemostasis [13]. Fresh frozen plasma should be
added to assist the recovery of clotting factors. The
dosage of dalteparin was titrated up to 350 U/kg twice
daily to reach a target anti-Xa level of 0.5 to 1.0. We also
prescribed supplemental 81 mg aspirin once daily. Other
emerging modalities have been used to treat acute infec-
tious and neonatal PF and may be applicable in some
cases of idiopathic PF, including protein C replacement,
anti-thrombin III replacement, prostacyclin and even
leech therapy [3,14]. Long-term management must
include physical therapy to assist with weight-bearing if
there is any evidence of contracture.
Responses to treatment in the referenced cases were
similar to those of our patient. Lesions regressed as early
as one day after therapy was initiated. Protein C and pro-
tein S levels often took weeks to months to return to nor-
mal reference levels. As noted in Table 3 some patients
lost extremities to gangrene, emphasizing the need for
immediate initiation of anti-coagulation as well as surgi-
cal excision of gangrene to prevent subsequent sepsis.
Conclusion
We report the first known case of idiopathic PF without
protein C or S deficiency and necessitating chronic anti-
coagulation. Pediatric patients presenting with indolent,
symmetric, necrotic, eschar-like lesions who have an
unrevealing infectious, inflammatory and hematologic
Table 2 Differential diagnosis of necrotic skin lesions in
an infant
a
System Diagnoses
Hematologic Idiopathic thrombocytopenic purpura
Thrombotic thrombocytopenic purpura
Coagulation factor deficiency
Platelet function disorder
Thromboembolic disease
Lupus/anti-phospholipid antibodies
Cryoglobulinemia
Porphyria
Idiopathic red blood cell agglutination
Idiopathic PF
Neonatal PF or other thrombophilic mutation
Infectious Cellulitis with or without atypical organisms or fungi
Endocarditis (bacterial, fungal or marantic)
Inflammatory Panniculitis secondary to a1-anti-trypsin deficiency
Pemphigus vulgaris
Pyoderma gangrenosum
Epidermolysis
Vascular HSP
Leukocytoclastic vasculitis
Hematoma with compartment syndrome
Neoplastic Leukemia
Lymphoma
Essential thrombocythemia
Cutaneous T-cell lymphoma
Nutritional Vitamin deficiency (vitamin K)
Mineral deficiency (zinc)
Environmental Toxic exposure (for example, heavy metals)
Congenital Combined immune deficiency
Prolidase deficiency
Leukocyte adhesion deficiency
Chronic granulomatous disease
g-globulinemia
Spinal muscular atrophy
Trauma
aPF, purpura fulminans; HSP, Henoch-Schonlein purpura.
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a
Case
report
Patient and
history
PS Trigger Treatment (target levels)
b Outcome and treatment
c
Boccara et
al. [15]
Two-year-old girl
Varicella three
months prior
Low HHV-6 IVIg 2 g/kg, LMWH, plasmapheresis q12 h, FFP (repeat IVIg if PS < 50%) Pre-treatment: right leg amputation
Post-treatment: resolution, IVIg 2 ×/day
Özbek et al.
[9]
Eight-year-old boy
FVL
+/-
G20210A
+/-
Low Not known Prior treatment: SQ UH, IV ceftriaxone, metronidazole
(One) Bolus 75U UH, 15 days continuous 20 U/kg/hour, twice daily FFP × 5 days
b
(Two) 80 to 100 U/kg SQ heparin for 1 month
(Three) Warfarin (INR Two or Three)
Pre-treatment: necrosis in lower half of body
Post-treatment: resolution
al-Ismail et
al. [10]
4.8-year-old boy
G20120A
+/-
ANA
+
ASO
+
Viral titer
-
Low Streptococcus? (One) Antibiotics, FFP, vitamin K
(Two) IV UH
(aPTT 1.5-2.5 × normal)
b
(Three) Enoxaparin 20 mg/q12 hours (anti-Xa level 0.6 U/L)
Pre-treatment: left leg swelling, edema, left
femoral vein thrombosis
Post-treatment: resolution
Levin et al.
d
[7]
6.4-year-old boy
Varicella
One year prior
Low Fever,
vesicular rash
(One) IV penicillin, cefotaxime, 4U FFP, IVIg 1 g/kg, exchange transfusion, methylprednisone, IV
heparin 15 U/kg/hour, tPa for PE, prostacyclin
(Two) IV heparin increased to 60 U/kg/hour, FFP 40 mL/kg/day (aPTT 1.5 to 2.5 × normal)
b
(Three) Warfarin
Pre-treatment: lesions stopped, right leg
amputation, PE
1
Post-treatment: then respiratory
improvement, resolution
5.9-year-old girl Low Varicella (One) IV cefotaxime, acyclovir and heparin bolus 100 U/kg/hour, then 25 U/kg/hour; two
volume exchange transfusion, then daily FFP
Pre-treatment: right atrial thrombosis, PE
e
Post-treatment: skin grafting
aPS, protein S; INR, international normalized ratio; HHV-6, human herpesvirus 6; IVIg, intravenous immunoglobulin; LMWH, low-molecular-weight heparin; FFP, fresh frozen plasma; PS, protein S; FVL, factor V Leiden;
G20210A, prothrombin G20210A mutation; SQ, subcutaneous; UH, unfractionated heparin; IV, intravenous; ANA, anti-nuclear antibody; ASO, anti-streptolysin O antibody; aPTT, activated partial thromboplastin time;
tPa, tissue plasminogen activator; PE, pulmonary embolism; +/-, heterozygote; +, antibodies present;
bmost effective treatment modality in each case when more than one treatment was applied;
cpre- and post-
treatment are with respect to most effective treatment in “Treatment (target levels)” column;
dLevin et al. [7] case series comprised five cases, but only two had sufficient clinical information both of which are shown
here;
eboth PEs occurred after initiation of effective treatment but before resolution, which occurred after indicated treatments.
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8work-up should undergo an empiric trial of anti-coagu-
lation to help prevent downstream catastrophic conse-
quences of PF. Starting anti-coagulation decisively may
also help to prevent developmental delays in rapidly
growing infants with this disease.
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